Management of Carfilzomib-Associated Cardiac Adverse Events

Joseph Mikhael

Research output: Contribution to journalComment/debatepeer-review

31 Scopus citations


Carfilzomib is a proteasome inhibitor that is approved for use as a single agent in patients with relapsed and refractory multiple myeloma and when used in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma (1-3 prior lines of therapy). Cardiac and cardiopulmonary adverse events have been reported to be associated with carfilzomib-based treatment regimens. This article discusses the cardiac-related adverse events that have been reported in clinical studies of carfilzomib and presents a single institution perspective on the prevention and management of cardiac adverse events following treatment with this agent.

Original languageEnglish (US)
Pages (from-to)241-245
Number of pages5
JournalClinical Lymphoma, Myeloma and Leukemia
Issue number5
StatePublished - May 1 2016


  • Cardiopulmonary
  • Clinical trials
  • Multiple myeloma
  • Proteasome inhibitor
  • Review

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Management of Carfilzomib-Associated Cardiac Adverse Events'. Together they form a unique fingerprint.

Cite this